C-Peptide Levels Linked to Type 1 Diabetes Complications

C-peptide is a marker of insulin production in the body. In people with type 1 diabetes, C-peptide levels are often low due to the autoimmune destruction of pancreatic beta cells.

Researchers have been studying the relationship between C-peptide levels and long-term clinical outcomes in people with type 1 diabetes.

A recent study published in Diabetes Care used data from the Scottish Type 1 Bioresource Cohort to investigate associations between baseline C-peptide levels and clinical outcomes.

The study included over 5,600 participants with a median diabetes duration of 21 years. Participants were followed for a median of 10.8 years.

The researchers found inverse associations between baseline C-peptide levels and the risk of diabetic ketoacidosis, severe hospitalized hypoglycemia, and retinopathy.

These associations persisted even after adjusting for time-updated glycosylated hemoglobin.

However, no association was found between baseline C-peptide levels and the risk of cardiovascular disease or death.

This suggests that while C-peptide levels may be linked to certain complications, they do not necessarily predict overall mortality.

Source: Diabetes care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.